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Recent studies in dogs have suggested that the disposition of S- and R-propranolol may
depend on the input rate of drug delivered to the liver. Therefore, this study was designed
to determine whether differences in the disposition of 5- and R-propranolol occur in hu-
mans when altering the input rate of propranolol by giving different dosage forms of the
drug. Twelve healthy subjects were enrolled in a single-dose, 4-way crossover pharmaco-
kinetic study in which racemic propranolol was given according to 1 of 4 treatments: one
80-mg immediate-release (IR) tablet, phase A; two 80-mg IR tablets, phase B; a 160-mg
controlled-release capsule, phase C; or a 10-mg IV bolus, phase D. The results showed no
significant differences in the ratios of S/R-propronolol for AUC, clearance, or overall
mean concentration among the oral dosage groups. Significant differences in these pa-
rameters including Cmox S/R ratio were seen between the oral phases and the IV phase.
These differences appear to be related more to the route of administration than to the low
input rate. However, at high concentrations there may be input-rate alteration in S/H
ratios. Specifically, for phase B, which had the highest Cm,,,, concentrations, the Cm,,x SIR
ratio was significantly lower than the other oral dosage groups A and C (Cmax S/H ratios:
1.44 versus 1.54 and 1.54, respectively; P <.05). These results suggest, as shown by the
Cmax S/R ratio, that at high concentrations as seen after 160-mg lB propranolol, the dispo-
sition of 5- and R-enantiomers may be different (i.e., input-rate dependent) compared with
dosage forms that result in lower drug concentrations. This may have important clinical
implications, because the pharmacodynamic response may be altered.
p ropranolol, a -adrenergic antagonist, is given as
a racemic mixture that undergoes extensive he-
patic metabolism and has a high extraction ratio.
There are significant pharmacokinetic and pharma-
codynamic differences between the two propranolol
enantiomers.’6 Specifically, studies have shown that
after oral administration, S-propranolol plasma con-
centrations may be greater, by 20% or more, than R-
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propranolol plasma concentrations.’6 The difference
in enantiomer concentrations is due to stereoselec-
tive metabolism with higher clearance for the R-iso-
mer. This results in an S/R-enantiomer clearance ra-
tio of less than one and S/R plasma concentration
ratios greater than one. Because the S-isomer con-
tains the majority of the I-blocking activity in hu-
mans, variability in the S/R ratio may have impor-
tant clinical consequences, such as altered blood
pressure and heart rate effect of the drug.7
Recent data in dogs suggest that the metabolism of
5- and R-propranolol may be input-rate dependent,
which when extrapolated to humans suggests that
the metabolism of these enantiomers and the resul-
tant S/R ratios may be dosage-form dependent.8 The-
oretically, differences in the rate of drug release be-
tween immediate- and controlled-release (JR and
CR) formulations may alter the disposition of S- and
R-isomers. For example, IR dosage formulations may
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lead to sufficiently high drug concentrations for he-
patic enzymes to become saturated, resulting in a
different rate of metabolism for the S- and R-enanti-
omers, as compared with formulations that lead to
lower concentrations that do not saturate the hepatic
enzymes, i.e., sustained-release and intravenous (IV)
dosage forms. Because alterations in the S/R ratios
may have clinical consequences, it is important to
determine whether propranolol enantiomer ratios
are input-rate dependent in humans. Therefore, this
study was designed to determine the effects of
different dosage formulations, and thus input rate, on
the disposition of propranolol enantiomers.
METHODS
Twelve healthy subjects (11 men; I woman) partici-
pated in this single-dose, four-way crossover study,
designed to evaluate the effect of drug input rate on
plasma enantiomer concentrations. After approval
from the hospital’s Institutional Review Board and
before study entry, informed consent was obtained
from each subject. The subjects ranged in age from
20 to 32 years (26 ± 4 years), and all were within 25%
of their ideal body weight. Health status for each sub-
ject was determined by a prestudy physical exam
and laboratory evaluation. Subjects were excluded if
they had a history of tobacco use, consumption of
any medications (including over-the-counter prod-
ucts), or xanthine-containing foods (including
caffeine) within 48 hours before each treatment
phase.
After an overnight fast, propranolol (Inderal;
Ayerst Laboratories Inc., New York, NY) was given
to the subjects according to 1 of 4 treatments: a single
80-mg IR tablet, phase A; two 80-mg IR tablets, phase
B; a single 160-mg CR capsule, phase C; or a 10-mg IV
injection, phase D. The infusion was given at a rate
of 1 mg/mm using an infusion syringe pump (model
2001; Medfusion, Duluth, GA). The oral doses were
given with 240 mL of water. There was a one-week
washout period between each treatment phase. A#{149}
standard meal was provided at four and nine hours
after dosing.
During treatment phases A, B, and G, 5-mL blood
samples were collected from a forearm venous cath-
eter into heparinized vacutainer tubes (Becton Dick-
inson, Rutherford, NJ) at 0 (predose), 0.25, 0.5, 0.75,
1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0, and 12.0 hours
after drug administration. During phase C, blood
samples were also obtained at 16 and 24 hours after
drug administration. During treatment phase D, 5-
mL blood samples were collected from a forearm ve-
nous catheter placed in the opposite arm in which
drug was being infused at 0 (predose), 0.083, 0.18,
0.22, 0.25, 0.33, 0.5, 0.6, 0.83, 1, 1.5, 2, 2.5, 3, 4, 6, 8,
10, and 12 hours after the initiation of the infusion.
Blood samples were centrifuged at 2000 rpm for 10
minutes. The plasma was then harvested and frozen
at _2OeC until it was assayed.
DRUG ANALYSIS
For determination of R- and S-propranolol, sodium
hydroxide with 3 mL of methyl-t-butyl ether was
added to the 0.5-mL plasma samples.9 After drying
the organic layer, the residue was reconstituted with
equal parts of 0.4% v/v triethylamine in acetonitrile
and 0.025% w/v 2, 3,4,5-tetra-o-acetyl-cr-d-glucopyr-
anosyl isothiocyanate in acetonitrile. After evaporat-
ing this mixture to dryness, 0.5 mL of mobile phase
was added (50% acetonitrile in 75 mmol/L ammo-
nium phosphate, pH = 3). After reconstitution a 100-
iL aliquot was injected onto a reverse phase, C-18
column. The flow rate of the mobile phase was 1.4
mL/min. The R- and S-enantiomers were detected
using a fluorometer at 216 nm excitation and 340 nm
emission. Assay sensitivity was between 2.5 ng/mL
and 150 ng/mL with a coefficient of variation of less
than 10% for each enantiomer.
DATA ANALYSIS
The area under the plasma concentration-time curve
from zero to infinity (AUC) and from zero to the last
measured time point (AUC0) was determined by the
linear trapezoidal method. The elimination half-life
(t112) was determined by linear regression analysis of
the terminal phase of the log concentration-time pro-
file. The apparent oral clearance (CL/f) for each iso-
mer was calculated by dividing one-half the admin-
istered dose by the AUC. The mean maximal plasma
concentrations (Gmax) and time to Cmax (tmax) were de-
termined by visual inspection of the available data
points. Overall mean concentration ratios were de-
termined by averaging the concentrations at each
time point for each patient within each phase. Sec-
ondary to the sustained-release pattern of the CR for-
mulation, no estimation of elimination rate was pos-
sible; therefore, no calculation of AUG (zero to infin-
ity) or oral clearance was possible. In addition, the
AUGO as reported in Table I should also be inter-
preted with caution for the CR formulation again ow-
ing to the variable absorption pattern. These limita-
tions do not greatly affect the study, because the pri-
mary objective was to evaluate enantiomer ratios
and not necessarily absolute numbers.
Statistical comparisons of the pharmacokinetic pa-
rameters for each isomer as well as the S/R ratios for
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Mean SIR Propranolol Isomer Ratios
Group Concentration AUC O-T C,,., CL/F
A 1.53±0.05 1.55±0.29 1.54±0.33 0.68±0.11
B 1.48±0.02 1.51±0.21 1.44±0.23t 0.70±0.11
C 1.44±0.08 1.52±0.36 1.54±0.43 -
D 1.23 ± 0.09* 1.20 ± 0.17* 1.14 ± 0.17t 0.88 ± O.13t
- not calculated; A 80mg immediate release; B = 160mg immediate
release; C = 160mg controlled release; 0 = 10mg intravenous in fusion.
* Dc ABC;P< .05.
f D<B<AC;P<.05.
1D>ABC;P<.05.
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Figure 2. Mean plasma concentration-time curves for R-propranolol.
among the oral dosage groups 9 of the 12 subjects had
a lower S/R ratio for Gmax in phase B as compared
with phase A and C.
In addition to evaluating overall mean concentra-
tion enantiomer ratios, individual ratios at each con-
centration-time point were also evaluated. Similar to
the overall mean concentration ratio, significant
differences were seen only between the oral and IV
phases. Specifically, S/R concentration ratios during
phase A were significantly higher than those during
phase D at the 2, 4, and 6 hour times points. Phases
A and B S/R concentration ratios were significantly
higher than that of phase D at the 1 hour time point.
Phases A, B, and G S/R concentration ratios were sig-
nificantly higher than those of phase D at the 3 and
10 hour time points. No significant differences were
seen among the oral treatment phases.
ous studies, our study showed that the R-isomer was
cleared more rapidly than the S-isomer (Table I). Be-
cause clearance of the R-isomer was greater for the
oral groups as compared with the IV group, this sug-
gests that the preferential removal of the R-isomer
probably occurs primarily during the first pass
through the liver, which occurs after oral admin-
istration.2 This results in differences not only for iso-
mer ratios but also for individual pharmacokinetic
parameters between the oral and IV phases. To prove
this explanation, however, evaluation of individual
extraction ratios of the isomers in viva are required.
Another potential explanation for the difference
between the oral and IV groups as postulated by Rose
et al. suggests that when portal/hepatic concentra-
tions of drug are low, the isomers are metabolized to
nearly the same extent.8 This contrasts with a situa-
tion where the rate of isomer presentation to the liver
is high (such as after IR dosing), in which hepatic en-
zymes may become saturated. Saturation of specific
isoenzymes for R and S metabolism probably occurs
at different concentrations depending on the isoen-
zyme’s respective Km. This will result in varying
plasma concentrations of the 5- and R-isomers. Our
data initially suggests that this may be another possi-
bility to explain the discrepancy in S/R ratios be-
tween the IV and oral groups based on the low con-
centrations (Cmax) seen after IV dosing. However, be-
cause the CR dosage group also had low
concentrations (lower than those of the IV phase) and
had significantly different enantiomer ratios from
the IV phase, this suggests that low drug delivery to
the liver in the concentrations observed does not
affect isomer metabolism and that presystemic clear-
ance accounts for the differences between oral and
IV phases. Therefore, it may be hypothesized that
low drug input rate does not affect 5- and R-isomer
disposition.
Though our findings show that the degree of ste-
DISCUSSION
In evaluating the effect of different dosage formula-
tions (and thus input rate) on enantiomer disposition,
this study showed no significant differences among
the oral dosage forms for concentration, AUC, or
clearance enantiomer ratios. However, significant
differences were seen between IV and oral routes.
Significant differences were also observed among the
oral dosage groups and to the IV group for Cmax en-
antiomer ratios.
The differences in enantiomer ratios between IV
and oral dosage forms can be explained in part by
the finding that R-propranolol is cleared to a higher
degree than S-propranolol in humans.16 Like previ-
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reoselective metabolism is not altered at low concen-
trations, this may not be the case at higher concen-
trations. From our data, the S/R Cmax ratio for the
160-mg IR dose (phase with the highest drug concen-
tration) suggests that alteration in stereoselective
metabolism may be occurring as compared with the
other oral dosage forms. One hypothesis for this, as
alluded to previously, is that a sufficiently high rate
of drug delivered to the hepatic system (i.e., after
high-dose IR formulation) will result in saturation of
the metabolizing enzymes. If the isoenzyme respon-
sible for metabolism is saturated, it may metabolize
S- and R-isomers to a different degree, as compared
with when one or neither isomer is fully saturated.
Further elucidation of this finding and the exact
mechanism (i.e., Km for specific isoenzymes) needs to
be addressed, especially because alteration in the S/
R ratio may result in alteration in pharmacodynamic
effects.
A factor in this study that partly limits our conclu-
sions is that additional doses providing higher con-
centrations as well as assessment at steady-state
must be done to determine whether alterations in S/
R ratios occur secondarily to the amount of drug de-
livered over time to the liver. The doses chosen for
this study were based on animal data and clinical ex-
perience. However, results in animals may not be
similar to those in humans, and higher doses may
also be used in the clinical setting. Therefore, as sug-
gested, other doses and regimens need to be studied.
Another potential limitation is that we may not be
able to detect a difference in bioavailability between
phase A and B owing to the variability observed (type
II error). However, we feel that clinically the small
difference in bioavailability between the groups is
probably not important.
In conclusion, the significant differences found in
the 5- to R-isomer ratios for plasma propranolol con-
centration, AUG, and clearance in the current study
are most probably due to the route of administration
and not to dose or dosage form. The ability of the IV
form to bypass the first-pass effect of the liver proba-
bly contributed to the lower clearance values and al-
teration in S/R ratio as compared with the oral dos-
age form. However, with the oral dosage forms, de-
crease in S/R ratio for Cmax in the 160-mg IR phase as
compared with the other 2 oral phases suggests that
at sufficiently high concentrations alterations in pro-
pranolol’s stereoselective metabolism may occur.
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